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ABSTRACT
Severe gingival overgrowth is one of the most frequent side effects in renal transplant patients associated with assumption 
of cyclosporine A. Several associations with age, sex, dosage, duration of therapy or interval since transplantation have 
been hypothesized. The introduction of alternative immunosuppressant drugs have been suggested to permit better 
long-term transplant outcomes and a decrease in incidence of  gingival overgrowth. The aim of the present paper is to 
summarize current knowledge regarding aetiology, pathogenesis and management of gingival overgrowth induced by 
Cyclosporine A.
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RESUMEN
El sobrecrecimiento gingival severo es uno de los efectos adversos más frecuentes en los pacientes con transplante renal 
asociado al suministro de ciclosporina A. Se han realizado hipótesis sobre diversas asociaciones con la edad, sexo, do-
sis, duración de la terapia o intervalo desde el transplante. Se ha propuesto la introducción  de la alternativa de drogas 
inmunosupresoras para permitir mejores resultados a largo plazo del transplante y la disminución en la incidencia de 
sobrecrecimiento gingival. El objetivo del presente estudio es resumir el conocimiento actual, observando la etiología, 
patogénesis y dirección del sobrecrecimiento gingival inducido por la ciclosporina A.
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INTRODUCTION 
Organ transplantation procedures necessitate the use of 
immunosuppressant drugs. Immunosuppressant therapy is 
prescribed in treatment of autoimmune diseases and pre-
vention of organ transplants rejection. The increased use 
of these medications has focused attention on the specific 
toxicities and side-effects associated (1, 2).
Since 1965, Merrill (3) performed in human beings the renal 
transplant and now it is considered a routine therapy for 
the treatment of irreversible renal failures. After renal trans-
plantation, it is mandatory beginning immunosuppressant 
therapy in order to create a condition in which lymphocytes 
are not active, to avoid renal transplant rejection (4).
Cyclosporine A (CsA) has been the primary tool to prevent 
the rejection of organ transplants. The clinical use of CsA 
is often complicated by several well documented side effects 
including gingival overgrowth (GO) (5, 6) (Table 1). 
The disfiguring GO may interfere with the normal oral 
functions and may also cause delayed and/or ectopic erup-
tion of teeth, impaired speech, headache appearance and 
difficulty in maintaining optimal oral hygiene resulting in an 
increased susceptibility to infections, caries, and periodontal 
diseases (7). Furthermore, these consequences may have a 
psychological impact in children and may in turn influence 
compliance with medical therapy.
In the last years, new drugs have been used to avoid renal trans-
plant rejection and to limit the well known side effects. Several 
studies indicate ‘improvement’ in GO when patients use new 
immunosuppressant drugs, such as Tacrolimus (FK506, Pro-
graf® Fujisawa, Japan), Rapamycin RS 61443 and Mycophe-
nolate mofetil (MMF) (CellCept®) (8), even if their collateral 
effects are not still extensively reported and, for this reason, 
CsA is still the mostly used drug in renal transplant therapy 
(9,10). However, there is evidence that use of Tacrolimus causes 
fewer oral side-effects than CsA (8,11,12). 
INMUNOSUPPRESSANT THERAPY
After renal transplant, the therapeutic schemes of immuno-
suppressant drugs are several: at first time, it is used to give 
high dose of drugs followed to a support period in which 
reducing dosage therapeutic till the lowest dosage possible. 
The protocol applied has varied from mono-therapy, (6-
metilprednisolone or CsA) to a combination of two drugs 
(CsA and cortisone or alternatively CsA and dihydropyri-
dine) up to the use of  three drugs (CsA, cortisone and 
azathioprine) (9,10). 
Among these drugs CsA is a non-myelotoxic immunosu-
ppressant and its primary target is helper/inducer T lympho-
cytes; azathioprine is a non specific myelosuppressive com-
monly used together with prednisolone (triple medication), 
dihydropyridines are calcium-channel blocking agents used 
in the management of cardiovascular disorders, which have 
been shown to suppress cell-mediated immunity (13, 14). Di-
hydropyridines may have a synergistic immunosuppressant 
effect on CsA therapy (15) and on CsA induced suppression 
of T-cell proliferation (16)  with the advantage of reducing 
the nephrotoxicity. Renal transplant patients are frequently 
treated with both CsA and  dihydropyridine.
The increased use of immunosuppressive medication has 
focused attention on the specific toxicities and side-effects 
associated with these agents. 
CYCLOSPORIN A
Cyclosporin (CsA) (Sandimmune® Novartis Pharmaceu-
ticals Corporation, Hanover, Germany) was introduced 
in 1972 thanks to Borel of  the Sandoz pharmaceutical 
company and registered in 1983. It is a lipophilic cyclic 
endecapeptide, isolated as an antifungal, from soil samples 
containing Cylindrocarpon lucidum BOOTH and Tolypo-
cladium inflatum GAMS (fungi imperfecti) (17). 
Table 1. Reported side effects of CsA.
� Nephrotoxicity � Hypertension 
� Hepatotoxicity � Biliary calculus disease 
� Diabetes � Neurotoxicity 
� Epilepsy � Hirsutism
� Tremors � Altered bone metabolism 
� Lingual fungiform papillae hypertrophy  � Gingival Overgrowth 
� Plasmocytoma  � Kaposi’s sarcoma 
� Squamous cell carcinoma of the lips � Cephalalgy 
� Sinusitis � Conjunctivitis 
� Hairy-leukoplakia 
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The molecular tertiary structure results in the formation of 
hydrophilic immunosuppressant binding site and reduces 
immunosuppressant potential (18,19). CsA is variably ab-
sorbed in the gut and peak plasma concentration is reached 
after 3-4 hours. The drug is mostly bound to the following 
cells: 50% erythrocytes, 5% lymphocytes and 40% lipopro-
teins (20), with approximately 5% free in the plasma (7). CsA 
is metabolised in the liver microsomes (21), and excreted 
after 6 hours mainly via the bile, through the faeces (22).
In vitro and in vivo experiments indicated that CsA interfe-
res selectively on T cell, particularly it inhibits T helper cells 
and it has get or no effect on T suppressor cells (23-25).
CsA inhibits selectively macrophage activation and IL-1 
production, it prevents production of IL-1 receptors on T 
helper cells (26), inhibits IL-2 synthesis at low concentra-
tions limiting clonal amplification of citotoxic T cell, and it 
inhibits their ability to respond to IL-2 (probably blocking 
cell surface receptors) (27).
CsA passively diffuses through cell membranes of many cells 
(including all peripheral blood lymphocytes and erytrocytes) 
and is concentrated in cytoplasm and nucleus (7). 
The pharmacokinetic problems due to incomplete, unpre-
dictable and inadequate absorption of original formulation 
of CsA have brought to introduction of new microemulsion 
formulation of CsA (Neoral), characterized to better ab-
sorption and a lower intra/inter-patient variability, permit-
ting a improved long-term transplant outcomes (28, 29).
PATHOGENESIS       
The pathogenesis of  CsA-GO is probably multifactorial 
and still uncertain. Some studies have suggested associa-
tions between incidence-severity of GO and sex (30), age 
at transplantation (31, 32), duration of therapy and CsA 
dosage, (33-35) significant drug-related risk factors for 
the development of the clinical conditions (31, 32, 36-38). 
There is a wide intra and inter-individual variability in the 
susceptibility of the CsA to induce GO (CsA-GO) (range 
30 to 50%) (39) and regularly it appears in more than 70% 
of adult transplant patients (31, 40). 
It has been reported that CsA is able to alter the metabo-
lism of  human gingival fibroblasts (41) and the lamina 
propria extracellular components. Histologically, gingival 
hyperplasia is associated with an increase in the deposition 
of intercellular matrix, in the percentage of inflammatory 
cells (particularly macrophages, also known as Langerhans 
cells), and in the degree of tissue vascularization(42-46). 
This inflammatory response is increased by the presence of 
dental plaque, suggesting that the hyperplasia can represent 
a response to the bacterial toxins (47, 48).
Some studies have suggested that this type of GO is related 
to an individual drug or metabolite susceptibility (5) since 
gingival fibroblasts show an individual drug response (49). It 
is possible that CsA and its metabolites react with a phenoty-
pically distinct subpopulation of gingival fibroblasts causing 
an increase in protein synthesis and rate of cell proliferation 
(50, 51). However, fibroblast heterogeneity has been de-
monstrated in relation to collagenase activity suggesting that 
CsA-GO involves an increase in the amount of collagen and 
extra cellular matrix formation (52) rather than an increase 
in the number of fibroblasts (53); this is could be a strange 
condition because IL-6 inhibits fibroblast proliferation (by 
the inhibiting of stimulatory cytokines) (54). 
Morton et al. (55) found that gingival fibroblasts respond 
to CsA increasing IL-6 secretion, which itself  enhances co-
llagen and glycosaminoglycan synthesis. They also observed 
that CsA synergizes with IL-1ß to further up-regulated IL-6 
secretion asserted that one of the pathogenic mechanisms 
underlying drug-induced GO might be enhanced secretion 
of IL-6 by gingival fibroblasts (55). It has been reported 
that gingival fibroblasts produce considerable quantity of 
IL-6, especially after stimulation with bacteria or other 
cytokines (56). 
In renal transplantation patients (57) increased levels of 
IL-6 have been reported, (58,59), but the cellular origin 
of IL-6 in CsA-GO is unknown. Although immune cells 
such as lymphocytes and monocytes could be the source 
of this cytokine, it is evident that the substantial rise in 
IL-6 activity in renal transplant or gingival tissues of CsA-
treated patients cannot be attributed to inflammatory cell 
infiltrates (60, 61). 
In relation to phagocytosis, fibroblasts from CsA-GO 
showed reduced phagocyte activity in inflamed tissue, as 
a result of lower proportions of phagocytes (35, 62). An 
increased rate of synthesis coupled with a decreased rate of 
phagocytosis would result in an evident increased amount 
of essential substance and it could explain the increase of 
connective tissue volume in CsA-GO.
Hence, it is possible to hypothesize that those individuals 
treated by CsA and genetically susceptible to GO, have 
got an appropriate mixture of fibroblast and lymphocyte 
subpopulations, as being able to  interact with CsA in 
inflamed gingival tissue, up to the well known GO clinical 
manifestations (63).
CSA THERAPY IN AUTOINMUNE DISORDERS 
AND ORAL SIDE EFFECTS
CsA is increasingly used, not only in transplantation practice 
but, also, in autoimmune disorders (i.e. psoriasis, systemic 
lupus erythematous, rheumatoid arthritis and multiple 
sclerosis) causing equally various side effects as in the oral 
cavity. In this district, the rare lingual fungiform papillae 
hypertrophy (LFPH), GO (64, 65), opportunistic infections, 
hairy leukoplakia (66, 67) and squamous cells carcinoma 
of the lip (67) have been repeatedly reported. Many studies 
have examined interaction of CsA with gingival fibroblasts, 
reporting a correlation between CsA effects on fibroblasts 
and extra-cellular components of connective lamina propria 
and GO; in fact, gingival fibroblasts show an individual 
response to the drug (68). Clinically gingival hyperplasia 
begins at the interdental papillae, more commonly in ante-
rior than in posterior region, and frequently on labial than 
on lingual surfaces (30,  69, 70).
Hyperplasia is often limited on adherent gingiva, but it may 
to extend coronally and interfere with occlusion, mastication 
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and language, without necessarily altering the underlying 
periodontium. Hyperplasia origin is apparently due to many 
factors: age, dosage, time of CsA assumption and possible 
additional other drugs. CsA-GO has not been described in 
edentulous patients or in edentulous space (40,71), even if  
few authors have reported CsA-GO in edentulous patients 
(71-75); in these latter cases an association of the hyperplasia 
emerges with denture trauma or candidal infection (71).
RISK FACTORS ASSOCIATED WITH SEVERITY 
OF GINGIVAL OVERGROWTH
Serum and salivary concentrations, dosage of  the drug, 
time since transplantation and assumption of drug, age, 
concomitant medication and oral hygiene are some the 
main risk factors influencing the severity of GO in renal 
transplantation patients.
SERUM CONCENTRATION AND DOSAGE 
This point has been discussed in controversial manner: some 
authors have found a correlation between the dosage of CsA 
and development severity of GO (34, 76), while others have 
reported contrasting findings (7, 42,78,79). There is a general 
agreement that an initial threshold serum concentration is re-
quired to initiate GO and it has been suggested that the higher 
is the serum concentration the quicker GO develops (76).
SALIVARY CONCENTRATION
Salivary concentrations of CsA are higher in patients taking 
the liquid form of the drug compared to the capsule form, 
but salivary concentrations are poorly correlated with blood 
levels (80).
TIME OF ADMINISTRATION
The relationship between GO and time of administration 
is another controversial issue since GO has been reported 
both in patients taking CsA within three months (34) or 
more (5). But, a recent report in children indicated that only 
subjects taking CsA for more than three months showed in 
all cases GO (81).
DURATION
Duration of CsA therapy has been reported to increase the 
chance to have GO. Recently, a significant inverse correla-
tion between periodontal status and duration of therapy has 
been reported, thus the negative effects of the drug could 
spontaneously decrease over time (82).
AGE AND SEX
Prevalence and severity of  GO has been reported to be 
significantly higher in children in comparison to the adults 
undergoing organ transplants. (79, 83). The immature fi-
broblasts, probably, are more sensitive to the effect of CsA 
(84, 85), so the increase GO in adolescents can be due to an 
interaction between circulating androgens, estrogens and 
gingival fibroblasts. Studies seem to suggest that children, 
especially adolescents and females may be more susceptible 
to this undesirable effect than adults (42, 86) The high-level 
of sexual hormones found in patients of this age produce 
an active metabolite (5 alpha-dihydrotestosterone) that acts 
on a subpopulation of gingival fibroblasts as being to the 
increase collagen synthesis and/or to decrease the collagenase 
production (87). In addition to the potential effect of hormo-
nes in adolescence, there is evidence that GO is influenced by 
orthodontic appliances which may irritate the soft tissues and 
act as a plaque trap thereby increasing the GO (88).
COMBINATIONS OF MEDICATIONS ASSOCIA-
TED WITH GINGIVAL OVERGROWTH
The most common combination of drugs that cause GO is 
CsA and nifedipine. Nifedipine is used habitually to treat 
hypertension which may be primary or secondary to CsA 
nephrotoxicity (36, 89). A significant increase in the inci-
dence of GO has been described in renal transplant patients 
taking nifedipine and CsA compared with those taking CsA 
alone (51 per cent vs 8 per cent) (90).
GENETIC PREDISPOSITION
The role of  individual susceptibility to GO has recently 
attracted much attention. Several studies (32, 37, 38) have 
described slight disease association between HLA alleles 
(A19, A24 and DR-2), and a possible protective effect of 
HLA-B37 and DR-1. The selectivity of the overgrowth to 
particular regions of the mouth and only in some patients, 
suggested a genetic predisposition that may interact with 
the local environment resulting in GO (39). 
ORAL HYGIENE
It is well known that dental plaque is composed of an aggre-
gation of micro organisms deposited on the tooth surfaces 
and it is able to begin inflammatory changes in the gingival 
tissues. Mediators of the inflammatory response cause the 
changes in gingival tissues (91). These inflammatory changes 
may increase the interaction between CsA and fibroblasts 
leading to changes in connective tissue turnover. The impro-
vement of general standard of oral hygiene can reduce GO 
resolving the inflammatory component plaque induced. In 
a longitudinal study, the effect on GO-CsA of a given oral 
hygiene program was examined in adult transplant patients 
(92): both the oral hygiene and the control group registered 
a significant gingival change, however, the degree of GO was 
less marked in the group with oral hygiene program. 
Although the role of plaque has not been clearly defined 
consistently with other several authors (93-96), the hyper-
plastic tissue tends to aid plaque accumulation and to inhibit 
plaque removal, increases the gingival inflammation. 
M A NAG E M E N T  O F  G I N G I VA L  OV E R -
GROWTH
Different therapeutic approaches for GO management have 
been proposed. The use of specific oral hygiene programs, 
surgical intervention and/or alternative pharmacological 
therapy have been reported.
Severe oral hygiene measures may reduce the degree of GO, 
but they do not inhibit its development.
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The need for surgical treatment to be carefully assessed. Sur-
gery is normally performed for cosmetic/aesthetic requests 
before any functional need is showed. In cases where drug 
therapy must be continued for several years, psychosocial 
support need to be considered with the purpose to reduce 
the frequency and extension of surgical interventions. 
Reduction in the dose of CsA has been shown to be be-
neficial versus GO  but, frequently, the nature of organ 
transplants does not permit an alternative therapy or dose 
reduction (97). 
When possible, alternatively to CsA, some patients can 
use other immunosuppressant drugs such as tacrolimus 
(FK506), azathioprine and rapamycin that may offer some 
hope not reporting GO associated. There is evidence to 
support the use of Tacrolimus over CsA since it has shown 
to cause fewer oral side-effects than CsA (11, 12), even if  
tacrolimus  may stimulate formation of cyst in anterior site 
of mouth and increase infections by Human Papilloma Vi-
rus, xerostomia, and oral ulcers (67). Tacrolimus/FK 506, 
a macrolide molecule, acts primarily on CD4+ T helper 
lymphocytes by inhibiting the production of lymphokines, 
which are required for cell growth and differentiation, 
principally of IL-2, at the transcriptional level (98). It has 
also been suggested that the elimination of CsA and its 
replacement of Tacrolimus removes the up regulation of 
CsA-induced essential polypeptide growth factors, which 
are important mediators in development of GO (99).
CONCLUSION
CsA is an immunosuppressant used widely for its rejection-
preventing power in human organ of transplantation (7, 
100). One of the side effects associated with CsA treatment 
is GO; CsA-GO is generally associated with acute or chro-
nic inflammation due to plaque accumulation (101, 102), 
reported dosage of CsA (103), presence of local gingival 
inflammation and gingivitis as independent predictors of the 
extent/severity of GO. An individual genetic susceptibility 
can be more or less responsible of the clinical manifestation 
of GO.
The present paper is drawn to underline the etiological re-
lationships and clarify some important aspects on the risk 
factors responsible of  CsA-GO in renal transplantation pa-
tients. In the future, dosage reduction and/or replacement of 
CsA with alternative efficacious pharmacological therapies 
to the CsA will undoubtedly taken into account in order to 
improve the oral health in these patients.
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